Type 2 diabetes in adults: management (medicines update) Guideline update – committee meeting 7

Date: Monday, 26th April 2021

Location: Virtual committee meeting by Zoom

Minutes: Final

Committee members present:			
Chizo Agwu (CA)	Chair	Present for notes 1 – 6	
Sarah Ali	Consultant Diabetologist	Present for notes 1 – 6	
Chirag Bakhai	GP	Present for notes 4 – 6	
Neel Basudev	GP	Present for notes 1, 2, part of 3 and 4 – 6	
Augustin Brooks	Consultant Diabetologist	Present for notes 1 – 3 and part of 4	
Anne Dornhorst	Consultant Diabetologist	Present for notes 1, 2, part of 3 and 4, 5 – 6	
Hugh Gallagher	Renal Physician	Present for notes 1 – 5	
Natasha Jacques	Pharmacist	Present for notes 1 – 6	
Sallianne Kavanagh	Pharmacist	Present for notes 2 – 6	
Sharon McCarthy	Diabetes Nurse	Present for notes 1 – 6	
Nicola Milne	Diabetes Nurse	Present for notes 1 – 6	
Soon Song	Consultant Diabetologist	Present for notes 1 – 6	
Annette Swinkels	Lay member	Present for notes 1 – 6	
Gosia Wamil	Cardiologist	Present for notes 1 – 6	

Corrinne Wykes	Lay member	Present for notes 1 – 6

NICE team in attendan	ce:	
Lucy Beggs (LB)	Technical Adviser (Health Economics)	Present for notes 1 – 6
Sarah Catchpole	Editor	Present for notes 1 – 6
Jacqueline Durkin	Administrator	Present for note 1 only
Gareth Franklin (GF)	Medicines Adviser	Present for notes 1 – 6
Rupert Franklin	Guideline Commissioning Manager	Present for notes 1 – 6
Chris Harris	Project Manager	Present for notes 1 – 6
Marie Harrisingh (MH)	Senior Technical Analyst	Present for notes 1 – 6
Ann Horrell	Senior Editorial Adviser	Present for note 5 only
Johanna Hulme (JH)	Associate Director Medicines Evidence and Advice	Present for note 5 only
Andrew Hutchinson (AH)	Technical Adviser - Medicines Education	Present for note 5 only
Thomas Jones (TJ)	Technical Analyst (Health Economics)	Present for notes 1 – 6
Gregory Moran (GM)	Technical Analyst	Present for notes 1 – 6

Apologies:	
Dorothy Frizelle	Mental health professional
Susan Spiers	Associate Director

1. Welcome, declarations of interest and minutes review

The Chair welcomed the Committee members and attendees to the seventh committee meeting on Type 2 diabetes in adults (medicines update).

The Chair informed the Committee that apologies had been received, noted above.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting, these are noted below. The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

Name	Job title,	Declarations of Interest,	Type of	Decision taken

	organisation	date declared	interest	
Neel Basudev	Committee member, Nurse	Member of the NHS London Kidney Network CKD Prevention steering group – part of the Early Identification workstream which involves case finding and improving urinary ACR data capture in primary care.	Direct, non- financial professional and personal	Declare and participate
Gosia Wamil	Committee member, Cardiologist	Private practice with a focus on the on the delivery of cardiac imaging and heart failure service, which reflects my NHS practice as a consultant cardiologist. Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work.	Direct financial	Declare and participate

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

2. Which pharmacological therapies are most effective at providing cardiovascular and other benefits in addition to blood glucose control in people with type 2 diabetes?

• Clinical evidence – trials

The Chair introduced Technical Analyst, Health, Greg Moran (GM), who gave a clinical evidence presentation to the committee summarising the characteristics of the included studies.

The Chair thanked Greg, for his presentation and the Committee for their comments and feedback.

3. Results of analyses:

- Pairwise meta-analysis
- Network meta- analysis

GM took the committee through the results of pairwise and network meta-analysis. The Chair thanked Greg for his presentation and the Committee for their feedback.

4. End of clinical results and discussions

GM completed his presentation and the committee discussed the results.

5. Integrating NICE Type 2 diabetes content to support decision making

The Chair introduced Johanna Hulme, Associate Director (JH), Andy Hutchinson, Technical Adviser (AH) and Gareth Franklin, Medicines Adviser (GF) who gave a presentation on integrating the NICE Type 2 diabetes content to support decision making.

The Chair thanked the presenters and the committee for their feedback.

6. AOB

The Chair thanked the committee for their contribution, summarised the main actions from the day and asked if there was any other business.

As there was no further business, the Chair highlighted the date of the next meeting and brought the meeting to a close.

Date of next meeting:	Thursday 3 rd June 2021 at 9.30am		
Location of next meeting:	Virtual committee meeting by Zoom		